Showing results (191-200 of 214) with videos related to
Sort By:
Pageof 22
Cancer Research|September 1, 1992
Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemiaS M Kornblau, H J Xu, A del Giglio, et al.Cancer|December 14, 1999
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patientsS Sacchi, H M Kantarjian, S O'Brien, et al.Blood|June 11, 1999
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemiaS O'Brien, H Kantarjian, C Koller, et al.Blood|January 1, 1988
Phenotypic and molecular heterogeneity in Philadelphia chromosome-positive acute leukemiaC Hirsch-Ginsberg, C Childs, K S Chang, et al.Cancer|August 15, 1988
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemiaR S Walters, H M Kantarjian, M J Keating, et al.Bone Marrow Transplantation|March 30, 2004
Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemiaP Mittal, R M Saliba, S A Giralt, et al.Blood|October 1, 1996
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemiaM Beran, H Kantarjian, S O'Brien, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemiaF J Giles, J E Cortes, S D Baker, et al.Cancer|October 12, 2001
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimensM Beran, Y Shen, H Kantarjian, et al.Blood|July 1, 1994
Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemiaS M Kornblau, H J Xu, W Zhang, et al.Pageof 22